You are browsing articles on the topic of Interventional Cardiology Archives - CardioExchange

Avatar of Sunil Rao, MD

Radial Access for PCI in Women: A Registry-Based Randomized Trial (18 Aug 2014)

Voices

Sunil Rao, MD, Harlan M. Krumholz, MD, SM, and John Ryan, MD

Harlan Krumholz and John Ryan interview Sunil Rao, lead author of SAFE-PCI for Women, a registry-based randomized trial of a radial versus a femoral approach to PCI.

Avatar of Larry Husten, PHD

Large Analysis Supports Thrombolysis for Stroke (5 Aug 2014)

News

Although thrombolysis for ischemic stroke has been widely recognized as beneficial, its use has been limited because of concerns about its effects in patients treated after 3 hours, in older patients, and in patients with mild and with severe strokes. Now a meta-analysis published in the Lancet offers evidence that the use of thrombolysis should be…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Peter

Can Bivalirudin Stand the HEAT? (14 Jul 2014)

Voices

Peter B Berger, MD

Harlan Krumholz interviews Peter Berger, an editorialist for the HEAT-PPCI study, about the paper’s findings.

Avatar of Richard A. Lange, MD, MBA

Do FFR and IVUS Feed the Elephant? (11 Jul 2014)

Voices

Richard A. Lange, MD, MBA and L. David Hillis, MD

Rick Lange and David Hillis wonder whether the debate about the role of FFR and IVUS in patient selection for PCI is a red herring in the larger issue of revascularization in patients with stable CAD.

Avatar of Larry Husten, PHD

HEAT-PPCI: Heparin Beats Bivalirudin in Primary PCI (7 Jul 2014)

News

Although there is broad consensus in the medical community that primary PCI is the best treatment for MI patients when it can be delivered promptly, there is no agreement about the best accompanying drug regimen, which usually entails a combination of antiplatelet and antithrombotic drugs. The role of one antithrombotic, bivalirudin (Angiomax, The Medicines Company) has…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Registry Study Offers Reassurance About Newer Drug-Eluting Stents (30 Jun 2014)

News

Findings from a large ongoing registry study provide some reassurance about the long-term safety of new-generation drug-eluting stents (DES)  in patients with STEMI who undergo primary PCI. The results are published online in the Journal of the American College of Cardiology. SCAAR (Swedish Coronary Angiography and Angioplasty Registry) investigators analyzed data from 34,000 primary PCI patients…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Physician's First Watch, CardioExchange Staff

To Screen or Not for AF: Is That the Question? (26 Jun 2014)

News

Up to one third of ischemic strokes are of uncertain etiology or “cryptogenic,” meaning that there is no overt explanation such as severe carotid stenosis, intracranial stenosis, or documented atrial fibrillation (AF). For some of these patients, intermittent AF may be present and could explain the ischemic stroke. This issue has been addressed by two…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Yet Another Delay for Boston Scientific’s Watchman Device (18 Jun 2014)

News

Boston Scientific hopes the third time will be the charm. The company disclosed on Tuesday yet another obstacle in the path to approval for its novel Watchman left atrial appendage closure device for the prevention of stroke in patients with atrial fibrillation. Although it has already been before two FDA advisory panels, the company said…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Approves Second-Generation Heart Valve from Edwards Lifesciences (17 Jun 2014)

News

The next phase of the burgeoning and rapidly maturing transcatheter aortic valve replacement (TAVR) market has begun. Edwards Lifesciences announced on Monday afternoon that the FDA had approved its second-generation Sapien XT TAVR device  for the treatment of high-risk and inoperable patients suffering from severe symptomatic aortic stenosis (AS). The Sapien XT is the successor to the first-generation Sapien device,…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Advisory Panel Supports Novel Drug-Coated Balloon (13 Jun 2014)

News

The FDA’s Circulatory System Devices advisory panel voted unanimously on Thursday to support approval of CR Bard’s Lutonix Drug-Coated Balloon (DCB). It would be used to enlarge arteries in a subset of patients who have peripheral arterial disease — including obstructive de novo or nonstented restenotic lesions (≤ 15 cm in length) in native femoropopliteal arteries…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.